Markets:

Overview

News

Currencies

International

Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Seagen Inc. (NASDAQ: SGEN) is a Leading Gainer in 12/12 Morning Trading

December 12, 2023

Via Investor Brand Network

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

December 10, 2023

From Seagen Inc.

Via Business Wire

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

December 06, 2023

From Seagen Inc.

Via Business Wire

Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High

October 23, 2023

Via Investor Brand Network

Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High

September 25, 2023

Via Investor Brand Network

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

November 30, 2023

From Seagen Inc.

Via Business Wire

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 03, 2023

From Seagen Inc.

Via Business Wire

New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate

November 02, 2023

From Seagen Inc.

Via Business Wire

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

November 01, 2023

From Seagen Inc.

Via Business Wire

Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Tuesday Session

October 24, 2023

Via Investor Brand Network

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

October 22, 2023

From Seagen Inc.

Via Business Wire

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

October 22, 2023

From Seagen Inc.

Via Business Wire

Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

October 20, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END

Via FinancialNewsMedia

Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023

October 16, 2023

From Seagen Inc.

Via Business Wire

Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

October 12, 2023

From Seagen Inc.

Via Business Wire

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

October 11, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END

Via FinancialNewsMedia

5 Stocks That Have Massive Upside According to Analysts

September 28, 2023

Analyst ratings are frequently a solid predictor of future stock price movement; here are five stocks that analysts believe have massive upside.

Via MarketBeat

Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Friday Session

September 22, 2023

Via Investor Brand Network

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

September 22, 2023

From Seagen Inc.

Via Business Wire

Flee to Healthcare Stocks if Recession Rears its Head?

September 20, 2023

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

Via MarketBeat

Topics Economy

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone

September 04, 2023

From Seagen Inc.

Via Business Wire

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

September 04, 2023

From Genmab A/S

Via Business Wire

Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

August 16, 2023

From Seagen Inc.

Via Business Wire

3 Pharmaceutical Stocks to Buy and Hold for the Long Haul

August 11, 2023

Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains

Via MarketBeat

Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum

August 02, 2023

From Seagen Inc.

Via Business Wire

3 Undervalued Large-Cap Stocks That Won't Be for Long

July 20, 2023

Buying undervalued stocks that have unrealized catalysts will rarely disappoint investors who have the discipline to hold them over time.

Via MarketBeat

Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023

July 12, 2023

From Seagen Inc.

Via Business Wire

Activision Blizzard Shares up 1.83% Amid Regulators' Blunders

June 27, 2023

Shares of Microsoft Corp. (NASDAQ: MSFT) declined 1.92% on June 26, more than the broader market, while Activision Blizzard Inc. (NASDAQ: ATVI) rose 1.83%. The S&P 500 declined 0.41% in the session.

Via MarketBeat

Topics Stocks

ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials

June 26, 2023

ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t

Via MarketBeat

Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

June 20, 2023

From Seagen Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.